Indicators: (1) Usage and mean duration of oral azithromycin before and after unrestriction; and (2) whether there is a decrease in quinolone use before and after unrestricting azithromycin.

Plan

Disciplines Involved: Antibiotic Stewardship Program

Monitoring Period: XXX – XXX

Sample Size: XXX patients at Campus and XXX patients at Campus according to SYBASE query listing.

Methodology: Retrospective reviews of antibiotic usage were conducted in patients who received oral azithromycin from XXX to XXX. The total numbers of patients on oral azithromycin, ciprofloxacin, moxifloxacin, and various other antibiotic combinations (i.e., azithromycin plus ceftriaxone, piperacillin/tazobactam, ciprofloxacin, or moxifloxacin) were calculated. Analyses were conducted to determine the usage and mean duration of oral azithromycin before and after unrestriction.

Do

Reports were generated using the SYBASE query listing all patients who received oral azithromycin, ciprofloxacin, moxifloxacin, piperacillin/tazobactam, and ceftriaxone between XX and XX.

Check

A total of XXX (nonexclusive) patients were included in this review (Table 1).

Table 1

Month

Month

Month

Campus

Mean duration of azithromycin (range), days of therapy

X (Y-Z)

X (Y-Z)

X (Y-Z)

Antibiotics

Number of Patients

Azithromycin PO

XX

XX

XX

Moxifloxacin PO

XX

XX

XX

Ciprofloxacin PO

XX

XX

XX

Campus

Mean duration of azithromycin (range), days of therapy

X (1-X)

X (1-X)

X (1-X)

Antibiotics

Number of Patients

Azithromycin PO

XX

XX

XX

Moxifloxacin PO

XX

XX

XX

Ciprofloxacin PO

XX

XX

XX

Table 2. Azithromycin PO and Ceftriaxone

Month

Month

Month

Campus

Number of patients

XX

XX

XX

Duration of azithromycin (range), days of therapy

X (1-X)

X (1-X)

X (1-X)

Campus

Number of patients

XX

XX

XX

Duration of azithromycin (range), days of therapy

X (1-X)

X (1-X)

X (1-X)

Table 3. Number of Patients on Azithromycin PO and Moxifloxacin

Month

Month

Month

Moses

XX

XX

XX

Weiler

XX

XX

XX

Table 4. Number of Patients on Azithromycin PO and Ciprofloxacin

Month

Month

Month

Moses

XX

XX

XX

Weiler

XX

XX

XX

Table 5. Number of Patients on Azithromycin PO and Piperacillin/ tazobactam

Month

Month

Month

Moses

XX

XX

XX

Weiler

XX

XX

XX

Figure 1. Comparison of Oral Azithromycin and Quinolone Usage at Campus, Before Unrestriction

Figure 2. Comparison of Oral Azithromycin and Quinolone Usage at Campus, After Unrestriction

Act

There was a trend of XX oral azithromycin usage comparing XX to XX after unrestriction.

There was a trend of decreasing oral moxifloxacin usage comparing XX to XX; however, it might be an artifact of seasonal change. Comparing XX to XX, the total number of patients on oral moxifloxacin did not change significantly.